• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics Inc (NQ: ARQT )

    8.100 -0.500 (-5.81%)
    Streaming Delayed Price Updated: 11:52 AM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 745,384
    Open 8.790
    Bid (Size) 8.100 (2)
    Ask (Size) 8.110 (1)
    Prev. Close 8.600
    Today's Range 8.080 - 9.096
    52wk Range 1.760 - 15.21
    Shares Outstanding 50,241,789
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
    Via Benzinga

    Performance

    YTD
    +136.15%
    +136.15%
    1 Month
    -13.83%
    -13.83%
    3 Month
    +21.99%
    +21.99%
    6 Month
    +264.86%
    +264.86%
    1 Year
    -46.00%
    -46.00%

    More News

    Read More
    Arcutis Appoints David Topper as Chief Financial Officer
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Leading the Way in Friday Trading Based on Percentage Gain
    Via Investor Brand Network
    EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Arcutis Promotes Todd Tucker to Chief Human Resources Officer
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Pricing of $150 Million Public Offering
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Proposed Public Offering
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.